title: Impaired stimulus-evoked mucus secretion in cystic fibrosis bronchi.
abstract: Baseline and agonist-stimulated secretion of fucose, hexose, and protein (markers of mucus secretion) was investigated in vitro in 45 bronchial segments from 14 patients with cystic fibrosis (CF) (three after heart-lung transplant, the remainder < 4.5 h after autopsy), in 51 segments from 26 patients with carcinoma (24 resection, 2 after autopsy), and in 4 segments from 3 patients with bronchiectasis (resection). Basal rates of secretion of each mucus marker by CF bronchi were not significantly different from those by carcinoma bronchi bronchiectatic bronchi. However, rates of secretion of each marker in response to the cholinomimetic methacholine (10 microM; n = 11-18, depending on marker) and the beta 2-adrenoceptor agonist terbutaline (10 microM; n = 9-11) were significantly (p < .05) increased in carcinoma bronchi (by 50-117% above basal), but not in CF airways (n = 11-14). The secretory response to the sensory neuropeptide substance P (1 nM to 10 microM; n = 5-7) was also reduced in CF compared with carcinoma bronchi. Physiological and morphological data indicated that the reduced response by CF tissue could not be accounted for by inclusion of autopsy tissue in the study. These data suggest a defect in autonomic control of bronchial secretion in CF, not in the basal rate of secretion, but in its response to receptor stimulation.
authors.affiliation: Department of Thoracic Medicine, National Heart and Lung Institute, London, England.
authors.forename: D F
authors.initials: DF
authors.lastname: Rogers
authors.forename: E W
authors.initials: EW
authors.lastname: Alton
authors.forename: A
authors.initials: A
authors.lastname: Dewar
authors.forename: M I
authors.initials: MI
authors.lastname: Lethem
authors.forename: P J
authors.initials: PJ
authors.lastname: Barnes
mesh_terms: D001344:Autopsy; D001481:Basal Metabolism; D001980:Bronchi / Q000187:drug effects* / Q000378:metabolism; D001987:Bronchiectasis / Q000503:physiopathology; D003550:Cystic Fibrosis / Q000503:physiopathology*; D005260:Female; D016041:Heart-Lung Transplantation / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D008175:Lung Neoplasms / Q000378:metabolism; D008297:Male; D009093:Mucus / Q000378:metabolism*; D011941:Receptors, Adrenergic / Q000187:drug effects*; D011950:Receptors, Cholinergic / Q000187:drug effects*; D013373:Substance P / Q000494:pharmacology*
chemical_list: D011941:Receptors, Adrenergic; D011950:Receptors, Cholinergic; D013373:Substance P